Kodiak Sciences to Participate in Upcoming Investor Conferences

Core Insights - Kodiak Sciences Inc. is focused on developing transformative therapeutics for retinal diseases and will present at upcoming investor conferences [1][2][3] Company Overview - Kodiak Sciences Inc. is a biopharmaceutical company dedicated to researching, developing, and commercializing therapeutics for retinal diseases, utilizing its proprietary ABCD Platform™ for drug development [3][7] - The company is advancing a portfolio of three clinical programs, with two in late-stage development and one expected to progress rapidly into pivotal studies [3] Investigational Medicines - Tarcocimab, Kodiak's lead investigational medicine, is an anti-VEGF antibody biopolymer conjugate being studied in two Phase 3 trials for diabetic retinopathy and wet AMD [4] - KSI-501 is a first-in-class bispecific antibody biopolymer conjugate targeting IL-6 and VEGF, currently in a Phase 3 study for wet AMD [5] - KSI-101 is a novel bispecific protein for retinal inflammatory diseases, with a Phase 1b study ongoing and plans for further Phase 2b/3 studies [6] Technology Platform - The ABCD Platform enables the development of high drug-antibody-ratio medicines by embedding small molecules into a proprietary biopolymer backbone, allowing for targeted and tailored therapeutic applications [7]